AstraZeneca and Oracle sign a non-binding AI collaboration, with a first programme on hypertension care and trial recruitment in Abu Dhabi

AstraZeneca and Oracle Health and Life Sciences launched a global AI collaboration that puts the drugmaker's clinical development and regulatory experience on the same working chain as Oracle's real-world data, cloud infrastructure and AI-enabled clinical capabilities for clinical research and care workflows. The stated starting point is that many serious conditions are diagnosed late, patients wait a long time before referral, and gaps exist in translating scientific advances into clinical practice; the collaboration is designed to test practical ways to connect research directly to clinical workflows. The listed initial areas of exploration are clinical trial recruitment, earlier diagnosis, drug-safety monitoring and use of real-world evidence, with programmes spanning AstraZeneca's core disease areas including oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology, and rare disease.

Implementation starts from a concrete setting: the first programme supports hypertension care and clinical research in Abu Dhabi with healthcare company M42, helping clinical teams identify patients with uncontrolled hypertension, implement guideline-directed care and improve clinical trial recruitment. This programme narrows the collaboration from a global framework to a single disease and a single region, giving the aim of connecting research and care a specific object to test. The collaboration will span multiple international projects in key regions including the US, Middle East and Europe, working with local governments and within applicable regulations so these could be scaled in the future.

Data use is limited to deidentified real-world data under governance, privacy and security arrangements, and AstraZeneca will not receive patient-identifiable information. Each proposed project will be reviewed separately and will proceed only once appropriate legal, privacy, regulatory, ethical and institutional safeguards are in place, so the collaboration is not a one-time blanket data sharing arrangement. The companies have signed a non-binding term-sheet agreement and no financials are being disclosed, so what can be confirmed is the collaboration framework and the first programme's direction rather than a completed deployment.

The confirmed scope is the global collaboration framework between AstraZeneca and Oracle Health and Life Sciences, the listed exploration areas, the covered disease areas, and the first programme on hypertension care and clinical research in Abu Dhabi with M42; the announcement gives no timeline, project count or outcome metrics.

The companies signed a non-binding term sheet and disclosed no financials; each project must be reviewed separately and proceed only after legal, privacy, regulatory, ethical and institutional safeguards are in place, so the announcement describes planned exploration rather than achieved results.